CSIMarket
 
Erasca Inc   (ERAS)
Other Ticker:  
 
 
Price: $2.1400 $0.06 2.885%
Day's High: $2.195 Week Perf: -4.46 %
Day's Low: $ 2.06 30 Day Perf: 23.7 %
Volume (M): 853 52 Wk High: $ 3.38
Volume (M$): $ 1,825 52 Wk Avg: $2.41
Open: $2.06 52 Wk Low: $1.51



 Market Capitalization (Millions $) 322
 Shares Outstanding (Millions) 150
 Employees 100
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -221
 Cash Flow (TTM) (Millions $) -106
 Capital Exp. (TTM) (Millions $) 3

Erasca Inc
Erasca Inc is a biotech company dedicated to discovering and developing innovative therapies for the treatment of cancer. The company was founded in 2018 and is headquartered in San Diego, California. Its mission is to eradicate cancer by developing precision medicines that target the root causes of the disease.

The core technology of Erasca is focused on precision medicine, which involves developing targeted therapies based on genetic and molecular information of individual patients. This technology allows the company to develop drugs that specifically target cancer cells, while minimizing harm to healthy cells in the body. Erasca has a number of proprietary drug discovery platforms that enable the development of these targeted therapies.

One of Erasca's flagship products is Erava, a targeted therapy designed to treat patients with solid tumors. This drug is currently in phase 1/2 clinical trials and has shown promising results in early testing. Erasca is also developing other products, including ERAS-007, a potential treatment for patients with KRAS-mutated cancer, and a range of antibody-drug conjugates (ADCs) that target different types of cancer cells.

The company's leadership team is composed of industry veterans with extensive experience in the development of oncology drugs. They bring a diverse range of expertise across drug discovery, clinical development, and regulatory affairs. Erasca has also formed strategic collaborations with leading institutions in the field of cancer research, such as MD Anderson Cancer Center and Children's Hospital Los Angeles.

Erasca has received significant support from institutional investors, raising more than $300 million in funding since its inception. The company is also committed to social responsibility, partnering with organizations like Stand Up To Cancer to help fund cancer research and raise awareness about the disease. Overall, Erasca represents a promising new entrant in the field of oncology drug development, with a strong focus on precision medicine and a commitment to making a meaningful impact in the fight against cancer.


   Company Address: 3115 Merryfield Row San Diego 92121 CA
   Company Phone Number: 465-6511   Stock Exchange / Ticker: NASDAQ ERAS
   ERAS is expected to report next financial results on March 22, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Naporafenib and Trametinib Combination in SEACRAFT Trials: Pioneering a New Era in Targeted Cancer Therapies

Published Wed, Feb 14 2024 1:00 PM UTC

In the quest for more effective treatments for RAS/MAPK pathway-driven tumors, Erasca Pharmaceuticals has announced two groundbreaking clinical trial collaboration and supply agreements for the evaluation of trametinib in combination with naporafenib. As a potential first-in-class and best-in-class pan-RAF inhibitor, naporafenib offers a promising avenue for combatting cance...

Product Service News

Naporafenib's Fast Track to Revolutionize NRAS-Mutated Melanoma Treatment and Transform Oncology Landscape

Published Mon, Dec 11 2023 1:00 PM UTC


Erasca Receives FDA Fast Track Designation for Promising Pan-RAF Inhibitor in NRAS-Mutated Melanoma
Erasca, a leading biopharmaceutical company, recently announced that its novel Pan-RAF inhibitor, Naporafenib, has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). This designation signifies the potential of Naporafenib as a first-in...

Clinical Study

Erasca Steps Closer to Revolutionary Therapy in Melanoma Treatment, Paving the Way for a Brighter Future

Published Tue, Nov 28 2023 1:00 PM UTC

Erasca's Groundbreaking Achievements in Naporafenib and ERAS-801 Programs Pave the Way for Innovation and Extended Cash Runway

Gained alignment with global health authorities for pivotal Phase 3 SEACRAFT-2 trial design for naporafenib plus trametinib in NRAS mutant melanoma; initiation on track for H1 2024

In a remarkable leap towards rev...

Erasca Inc

Erasca Inc. Emerges as a Powerhouse in the Pharmaceutical Industry with Impressive Third Quarter Earnings


As a leading financial publication, it is crucial for us at The to keep an eye on every aspect of the economy and bring our readers the most in-depth analysis. Today, we turn our attention to the overlooked corporations in the Major Pharmaceutical Preparations industry, specifically focusing on ERAS (Erasca Inc) and its recent financial results.
In an unexpected turn, ERAS announced an operating loss of $-34.658 million for the third quarter of 2023. This news has overshadowed the performance of other major companies in the industry during the same period last year. Although disheartening, it is essential to understand the unique circumstances surrounding ERAS that contributed to these results.

Erasca Inc

Erasca Inc. Demonstrates Robust Financial Growth with Remarkable Second Quarter Earnings in Major Pharmaceutical Preparations Market



After major pharmaceutical companies have reported their financial results, some lesser-known corporations are starting to make headlines in the industry. One such company is ERAS, which recently announced a decrease in its operating deficit for the second quarter of 2023. This improvement, along with positive predictions for revenue generation, suggests that ERAS could become a leading player in the healthcare sector. Additionally, we will take a look at ERAS's recent stock performance to gain further insight into the company's overall standing.
Article:
ERAS, a major player in the pharmaceutical preparations industry, has reported improved financial results, assuaging investor concerns. For the second quarter of 2023, ERAS announced an operating deficit of $-35.97 million, showing a contraction compared to the $-35.905 million deficit reported during the same period in 2022. This reduction signifies progress in managing expenditures and improving overall financial health.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com